Increased Th17 cells and IL-17A exist in patients with B cell acute lymphoblastic leukemia and promote proliferation and resistance to daunorubicin through activation of Akt signaling. This evidence concerns the gene AKT1 and B-cell acute lymphoblastic leukemia.